NFKB1 and breast carcinoma: Kollur et al. (2021) explained luteolin’s established cytotoxic mechanisms in breast cancer, involving ROS generation, DNA damage signaling, NF-κB inhibition, p38 activation, and apoptosis induction, offer a starting point for exploring its potential in AD and GBM, although the specific pathophysiology of each disease suggests distinct avenues for its action.